Boston Scientific
Boston Scientific Corporation, a leading global medical technology company, is headquartered in the United States. Founded in 1979, the company has established itself as a key player in the medical device industry, focusing on innovative solutions across various therapeutic areas, including cardiovascular, rhythm management, and urology. With a strong presence in North America, Europe, and Asia-Pacific, Boston Scientific is renowned for its advanced products and services, such as minimally invasive devices and cutting-edge imaging technologies. The company’s commitment to innovation is exemplified by its numerous milestones, including the development of the first drug-eluting stent. Recognised for its market leadership, Boston Scientific continues to push the boundaries of medical technology, enhancing patient outcomes and improving quality of life. Its dedication to research and development positions it as a trusted partner in healthcare worldwide.
DitchCarbon Score
How does Boston Scientific's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boston Scientific's score of 94 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boston Scientific's reported carbon emissions
In 2024, Boston Scientific reported total carbon emissions of approximately 87,567,000 kg CO2e for Scope 1 and 9,854,000 kg CO2e for Scope 2, resulting in a combined total of about 97,421,000 kg CO2e (market-based). The company has set ambitious climate commitments, aiming for carbon neutrality across all manufacturing and key distribution sites by 2030. This commitment includes a near-term target to reduce absolute Scope 1 and 2 greenhouse gas emissions by 46.2% from a 2019 baseline by 2030. Boston Scientific has achieved a significant reduction of 68% in greenhouse gas emissions since 2009 for both Scope 1 and 2. Additionally, the company has long-term goals to reduce Scope 1 and 2 emissions by 97% per USD value added, equating to a 90% absolute reduction by 2050. For Scope 3 emissions, Boston Scientific aims for a 55% reduction per USD value added by 2030, with a long-term target of 97% reduction by 2050. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Boston Scientific's commitment to addressing climate change and reducing its environmental impact. The company is on track to meet its near-term goals, reinforcing its position as a leader in sustainability within the healthcare equipment and supplies sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boston Scientific is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
